Clinical Development & Scientific Consultation
We are a specialty CNS CRO that supports all phases of development for novel drugs. We provide scientific leadership and have extensive experience with the CNS approval process.
Our Scientific Leadership Team reviews every new protocol at the bid stage to assess the potential study risks, and works directly with the Sponsor as well as the CRO Project Teams to mitigate them in advance of FPI and then continues to be available throughout the life of the trial. Every Lotus Study is assigned a Scientific Leadership Team member from this list of Clinicians, Research Experts, and Scientists.
Lotus is a science-driven, full-service CRO with a number of unique qualities that no other CRO can provide. One particular differentiator is that we are under common ownership with Evolution Research Group (ERG), which is a clinical site organization with 20+ wholly-owned clinical research sites around the US.
Because of this connection to ERG, Lotus’ Sponsors benefit from one-stop shopping for:
Baudax Bio Non-Opioid Pain Drug Approval: In February, FDA granted approval to longtime Lotus client/ collaborator Baudax Bio’s non-opioid postsurgical pain therapy ANJESO. Lotus designed
In September 2019, Lotus acquired HD Research, a network of specialty US analgesic research sites run by board certified anesthesiologists Harold Minkowitz, MD and David
The conduct of PONV clinical trials has significant impact on their assay sensitivity. This is in part due to the strict experimental controls needed to
